417 related articles for article (PubMed ID: 16492728)
1. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome.
Varga R; Eriksson M; Erdos MR; Olive M; Harten I; Kolodgie F; Capell BC; Cheng J; Faddah D; Perkins S; Avallone H; San H; Qu X; Ganesh S; Gordon LB; Virmani R; Wight TN; Nabel EG; Collins FS
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3250-5. PubMed ID: 16492728
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
Sánchez-López A; Espinós-Estévez C; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; Fanjul V; Riquelme-Borja R; Hamczyk MR; Macías Á; Del Campo L; Camafeita E; Vázquez J; Barkaway A; Rolas L; Nourshargh S; Dorado B; Benedicto I; Andrés V
Circulation; 2021 Nov; 144(22):1777-1794. PubMed ID: 34694158
[TBL] [Abstract][Full Text] [Related]
3. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
[TBL] [Abstract][Full Text] [Related]
4. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
Villa-Bellosta R; Rivera-Torres J; Osorio FG; Acín-Pérez R; Enriquez JA; López-Otín C; Andrés V
Circulation; 2013 Jun; 127(24):2442-51. PubMed ID: 23690466
[TBL] [Abstract][Full Text] [Related]
5. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
Hamczyk MR; Andrés V
Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
[TBL] [Abstract][Full Text] [Related]
6. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
8. Nuclear membrane ruptures underlie the vascular pathology in a mouse model of Hutchinson-Gilford progeria syndrome.
Kim PH; Chen NY; Heizer PJ; Tu Y; Weston TA; Fong JL; Gill NK; Rowat AC; Young SG; Fong LG
JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423791
[TBL] [Abstract][Full Text] [Related]
9. A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells.
Atchison L; Zhang H; Cao K; Truskey GA
Sci Rep; 2017 Aug; 7(1):8168. PubMed ID: 28811655
[TBL] [Abstract][Full Text] [Related]
10. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
11. Exacerbated atherosclerosis in progeria is prevented by progerin elimination in vascular smooth muscle cells but not endothelial cells.
Benedicto I; Carmona RM; Barettino A; Espinós-Estévez C; Gonzalo P; Nevado RM; de la Fuente-Pérez M; Andrés-Manzano MJ; González-Gómez C; Rolas L; Dorado B; Nourshargh S; Hamczyk MR; Andrés V
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2400752121. PubMed ID: 38648484
[TBL] [Abstract][Full Text] [Related]
12. Vascular smooth muscle cell-specific progerin expression in a mouse model of Hutchinson-Gilford progeria syndrome promotes arterial stiffness: Therapeutic effect of dietary nitrite.
Del Campo L; Sánchez-López A; Salaices M; von Kleeck RA; Expósito E; González-Gómez C; Cussó L; Guzmán-Martínez G; Ruiz-Cabello J; Desco M; Assoian RK; Briones AM; Andrés V
Aging Cell; 2019 Jun; 18(3):e12936. PubMed ID: 30884114
[TBL] [Abstract][Full Text] [Related]
13. Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.
Benedicto I; Dorado B; Andrés V
Cells; 2021 May; 10(5):. PubMed ID: 34064612
[TBL] [Abstract][Full Text] [Related]
14. Premature Vascular Aging with Features of Plaque Vulnerability in an Atheroprone Mouse Model of Hutchinson-Gilford Progeria Syndrome with
Nevado RM; Hamczyk MR; Gonzalo P; Andrés-Manzano MJ; Andrés V
Cells; 2020 Oct; 9(10):. PubMed ID: 33049978
[TBL] [Abstract][Full Text] [Related]
15. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
16. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
17. Hutchinson-Gilford progeria syndrome as a model for vascular aging.
Brassard JA; Fekete N; Garnier A; Hoesli CA
Biogerontology; 2016 Feb; 17(1):129-45. PubMed ID: 26330290
[TBL] [Abstract][Full Text] [Related]
18. Hutchinson-Gilford progeria syndrome.
Pollex RL; Hegele RA
Clin Genet; 2004 Nov; 66(5):375-81. PubMed ID: 15479179
[TBL] [Abstract][Full Text] [Related]
19. Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.
Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
FASEB J; 2015 Aug; 29(8):3193-205. PubMed ID: 25877214
[TBL] [Abstract][Full Text] [Related]
20. Low levels of the reverse transactivator fail to induce target transgene expression in vascular smooth muscle cells.
Viceconte N; McKenna T; Eriksson M
PLoS One; 2014; 9(8):e104098. PubMed ID: 25090270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
